Zika Stocks To Watch; $AEMD, $BCRX, $CERS, $INO; Virus Continues Spread
Point Roberts,
WA, Delta BC – August 22, 2016 – Investorideas.com, a global news source and
investor resource covering actively traded sectors including biotech and
medical technology stocks , releases its
Zika stocks directory for investors following the sector as the virus continues
its spread in the US.
As of this week,
Florida’s Governor reported five new non-travel-related cases of Zika virus and
the first one in the Tampa Bay area, now bringing the total to 42.
CDC report as of August 17, 2016
•Zika virus
disease and Zika virus congenital infection are nationally notifiable
conditions.
•This update
from the CDC Arboviral Disease Branch includes provisional data reported to
ArboNET for January 01, 2015 – August 17, 2016.
US States
•Locally
acquired mosquito-borne cases reported: 14
•Travel-associated
cases reported: 2,245
•Laboratory
acquired cases reported: 1
•Total: 2,260
◦Sexually transmitted: 22
◦Guillain-Barré
syndrome: 7
The
Florida Department of Health has identified two areas in Miami with active
transmission of Zika virus. See advice (http://www.cdc.gov/zika/intheus/florida-update.html) for people living in or traveling to these areas.
Zika Virus Stocks
Aethlon Medical, Inc. (NasdaqCM: AEMD) creates innovative medical devices to address
life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity
Platform Technology) establishes the basis for a new class of therapeutics that
target the rapid elimination of disease enabling particles from the circulatory
system of treated patients. The lead Aethlon ADAPT™ product is the
Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as
well as tumor-secreted exosomes that suppress the immune system of cancer
patients. Aethlon is also operating under two government contracts with
the Defense Advanced Research Projects Agency (DARPA) related the development
of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc.
is a majority owned Aethlon subsidiary that is advancing exosome-based
strategies to diagnose and monitor cancer and infectious disease progression.
Aethlon Medical (Nasdaq: AEMD) Announces Zika Virus
Data
In vitro studies that demonstrate the rapid capture
of Zika virus by the Aethlon Hemopurifier
SAN DIEGO - August 11, 2016- Aethlon Medical, Inc.
(Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat
infectious disease and cancer, announced today that its researchers have
completed in vitro studies that demonstrate the rapid capture of Zika virus by
the Aethlon Hemopurifier®. The Hemopurifier® is a leading broad-spectrum
treatment countermeasure against viral pathogens that are untreatable with or
resistant to antiviral drug therapies. At present, the immunotherapeutic
technology is being advanced through an FDA approved human feasibility study.
The Zika studies, which were conducted with small-scale versions of the
Hemopurifier®, demonstrated a 95% clearance of Zika virus from cell culture
fluid in 5.5 hours and an approximate 50% clearance of Zika from human blood
serum in 5 hours.
The studies were conducted with the Zika viral
strain that has recently spread from South America to ravage Puerto Rico and
likely responsible for the first wave of infections that have begun to occur in
the United States. Zika has been declared a global health threat by the World
Health Organization and is not addressed with a proven drug or vaccine therapy.
According to the CDC, more than 7,300 Americans have been diagnosed with Zika
virus infection, including 1,825 individuals in the continental U.S. and
Hawaii. Researchers have linked Zika virus infection with Guillain-Barre
syndrome, a severe neurological disorder that can cause paralysis. In pregnant
women, Zika can cause Microcephaly, which results in babies being born with a
small head and underdeveloped brain. Zika infection has also been associated with
Arthrogryposis, a condition that results in deformities of joints in the arms
and legs of newborns.
"As a result of our research team's validation
of Zika capture, we have further reinforced the potential of our Hemopurifier®
to be a first line of defense against the growing list of infectious viral
pathogens that are not addressed with traditional drug or vaccine
therapies," stated Aethlon Chairman and CEO, Jim Joyce.
BioCryst Pharmaceuticals (NASDAQ:BCRX) BioCryst Pharmaceuticals designs, optimizes and
develops novel small molecule drugs that block key enzymes involved in rare
diseases. BioCryst’s ongoing development
programs include oral plasma kallikrein inhibitors for hereditary angioedema;
BCX7353 and other second generation compounds, and BCX4430, a broad spectrum viral
RNA polymerase inhibitor. In March the Company announced that results from a
preclinical study of its broad spectrum antiviral BCX4430 in immune-deficient
mice infected with Zika virus would be presented at a World Health Organization
(WHO) meeting scheduled to take place March 7-9 in Geneva, Switzerland. The
primary goal of the study was to assess the effect of BCX4430 treatment on
survival through Day 28 in immune-deficient mice infected with the Zika virus.
BCX4430 was administered by intramuscular (I.M.) injection twice a day
beginning four hours prior to virus challenge and continuing for eight days;
two dose levels were tested. In the standard dose BCX4430 group, 7 of 8 mice
survived through Day 28. In the low dose BCX4430 group (n=8), and in control
groups administered vehicle placebo (n=8) or ribavirin at two dose levels
(n=16), no animals survived to Day 28. Overall survival for the standard dose
level of BCX4430 was superior to both the placebo and the ribavirin treatment
control groups (p < 0.0001). For both dose levels of BCX4430, median
survival was superior to both control groups (>28 days for BCX4430 standard
dose and 23 days for low dose) compared to 14 to 17 days for controls. This
study was conducted at Utah State University, under the ongoing Animal Models
of Infectious Disease Program at the National Institute of Allergy and
Infectious Diseases (NIAID), part of the National Institutes of Health. This
program provides in vivo screening services for researchers, as part of a
broader suite of preclinical services supported by NIAID. These services are
part of NIAID’s infrastructure for responding to emerging infectious diseases,
such as Zika virus, and allow for research to be quickly directed to support
immediate public health needs.
Cerus Corp. (NasdaqGM:
CERS) is a biomedical products company
focused in the field of blood safety. Cerus currently markets and sells the
INTERCEPT Blood System for both platelets and plasma in Europe, the
Commonwealth of Independent States, the Middle East and selected countries in
other regions around the world. In the United States, Cerus is seeking
regulatory approval of the INTERCEPT Blood System for plasma and platelets. The
INTERCEPT red blood cell system is in clinical development
GeneOne Life Science Inc. (KSE:011000.KS; KRX:011000.KR) a
biopharmaceutical company, engages in the research and development of DNA
vaccines to prevent and treat incurable diseases in South Korea and
internationally. Its product pipeline includes VGX-3400, a DNA vaccine, which
has completed Phase I clinical trials for the prevention of avian influenza;
VGX-3500, a prophylactic pre-pandemic influenza DNA vaccine that is in Phase I
clinical trials for protection against swine, avian, and seasonal influenza;
and FLUPRIME, a trivalent influenza vaccine, which is in Phase I clinical
trials for the prevention of the outbreak of seasonal flu. The company is also
developing VGX-6150, a therapeutic DNA vaccine that is in Phase I clinical
trials for the treatment of hepatitis C; and therapeutic DNA vaccines for the
treatment of hepatitis B. In addition, it is involved in the contract
manufacturing activities for various pre-clinical and clinical studies for
institutions, universities, governments, and biotechnology companies. GeneOne
Life Science Inc. has a collaboration with Inovio Pharmaceuticals, Inc. to test
and advance a DNA-based vaccine for preventing and treating the emerging and
virulent Zika virus infection. The
company was formerly known as VGX International Inc.
GLAXOSMITHKLINE PLC (NYSE:GSK) creates, discovers, develops, manufactures, and markets pharmaceutical
products, such as vaccines, over-the-counter medicines, and health-related
consumer products worldwide. The company provides pharmaceutical products in
various therapeutic areas, such as respiratory, anti-virals, central nervous
system, cardiovascular and urogenital, metabolic, antibacterials, oncology and
emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It
also offers consumer health products in total wellness, oral care, nutritional,
and skin health areas. In addition, it provides prescription medicines; and
paediatric and adult vaccines against various infectious diseases
Inovio Pharmaceuticals, Inc (NYSE MKT:INO) is
revolutionizing the fight against cancer and infectious diseases. Our
immunotherapies uniquely activate best-in-class immune responses to prevent and
treat disease, and have shown clinically significant efficacy with a favorable
safety profile. With an expanding portfolio of cancer immunotherapies and
clinical studies, the company is advancing a growing product pipeline. Partners
and collaborators include Roche, the University of Pennsylvania, NIH,
HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV
Research Program, US Dept. of Homeland Security, and University of
Manitoba.
Intrexon Corporation (NYSE:XON) is Powering the Bioindustrial
Revolution with Better DNA™ to create biologically-based products that improve
the quality of life and the health of the planet. The Company's integrated
technology suite provides its partners across diverse markets with
industrial-scale design and development of complex biological systems
delivering unprecedented control, quality, function, and performance of living
cells. We call our synthetic biology approach Better DNA®.
SANOFI-AVENTIS SA
(NYSE:SNY; Paris: SAN.PA) a global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients’ needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. https://lehub.sanofi.com/en/access-healthcare/zika-a-strong-sense-of-urgency/
About Investorideas.com - News that Inspires Big Ideas
Sectors we cover in include mining, energy,
renewable energy, water stocks, food and beverage (including organic and LOHAS,
wine), defense and security, biotech, technology and mobile. We have also
expanded our global coverage to include Latin American stocks, the Middle East,
sports and entertainment.
Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks,
renewable energy, nanotech, defense, technology, biotech and more – use our
stock directories and access them online 24/7 with login as a member to find
your next big idea!
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: AEMD - August 11, 2016 - one month of
PR. News publication and social media – two thousand five hundred
Additional info regarding BC Residents and global
Investors: Effective September 15 2008 - all BC investors should review all OTC
and Pink sheet listed companies for adherence in new disclosure filings and
filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each
country.
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment